- Home
- DRTS vs GOSS Comparison
DRTS vs GOSS Comparison
Compare DRTS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- GOSS
- Stock Information
- Founded
- DRTS 2015
- GOSS 2015
- Country
- DRTS Israel
- GOSS United States
- Employees
- DRTS N/A
- GOSS N/A
- Industry
- DRTS Medical/Dental Instruments
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- DRTS Health Care
- GOSS Health Care
- Exchange
- DRTS Nasdaq
- GOSS Nasdaq
- Market Cap
- DRTS 259.4M
- GOSS 212.8M
- IPO Year
- DRTS N/A
- GOSS 2019
- Fundamental
- Price
- DRTS $2.70
- GOSS $1.40
- Analyst Decision
- DRTS Strong Buy
- GOSS Strong Buy
- Analyst Count
- DRTS 2
- GOSS 5
- Target Price
- DRTS $8.00
- GOSS $9.20
- AVG Volume (30 Days)
- DRTS 108.6K
- GOSS 1.6M
- Earning Date
- DRTS 03-06-2025
- GOSS 03-04-2025
- Dividend Yield
- DRTS N/A
- GOSS N/A
- EPS Growth
- DRTS N/A
- GOSS N/A
- EPS
- DRTS N/A
- GOSS N/A
- Revenue
- DRTS N/A
- GOSS $105,322,000.00
- Revenue This Year
- DRTS N/A
- GOSS N/A
- Revenue Next Year
- DRTS N/A
- GOSS N/A
- P/E Ratio
- DRTS N/A
- GOSS N/A
- Revenue Growth
- DRTS N/A
- GOSS N/A
- 52 Week Low
- DRTS $1.75
- GOSS $0.50
- 52 Week High
- DRTS $4.39
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- DRTS 28.95
- GOSS 67.09
- Support Level
- DRTS $2.95
- GOSS $1.37
- Resistance Level
- DRTS $3.19
- GOSS $1.55
- Average True Range (ATR)
- DRTS 0.21
- GOSS 0.13
- MACD
- DRTS -0.08
- GOSS 0.03
- Stochastic Oscillator
- DRTS 3.85
- GOSS 75.81
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.